Meningococcal Meningitis
|
|
- Elaine Day
- 6 years ago
- Views:
Transcription
1 Meningococcal Meningitis By Lindsey Ream Etiologic Agent The disease meningococcal meningitis, also known as meningococcus, is caused by the bacteria Neisseria meningitidis (1). Disease occurs when the bacteria passes through the blood-brain barrier, and infects the cerebral spinal fluid, CSF, of the meninges in the central nervous system (4). Transmission Meningococcal meningitis is spread by droplets from the upper respiratory system during close contact between individuals (2). These droplets come from the bacteria s portal of entry and exit: the nose and mouth, and may be inhaled or ingested by a person due to coughing or kissing (3) (5). Once the infected droplets have been transmitted, they may penetrate the mucous membranes, entering the bloodstream and possibly the central nervous system causing disease (4). Reservoirs There are no other hosts of the disease except humans, and the reservoir is the human nasopharynx (6) (7) (9) (14). It is known that the bacterium attaches to respiratory cells of the mucous membrane in the nasopharynx, but the mechanism by which it enters the central nervous system is unknown (4) (8) (7). It is possible to be a carrier of N. meningitidis, and never develop disease, but it depends on several unknown factors (4) (7). General characteristics of microorganism N. meningitidis is an aerobic, Gram-negative diplococcal bacterium which appears to be kidney or coffee bean shaped (4) (9) (10). It has no structures for motility, but is encapsulated. It requires a complex nutrition supply provided by a blood (BAP) or chocolate agar plate (CAP) when cultured, and a specific environment for growth due to its fastidious nature: human body temperature and 5% CO 2 (10). The colonies that form when cultured on a BAP are round, smooth, moist, convex, and gray ; while the colonies that form on CAP are large, colorless-togray, opaque colonies (10). There are 12 serogroups based on the various capsular polysaccharides: A, B, C, H, I, K, L, X, Y, Z, 29E, and W135; the most virulent of which are A, B, C, X, Y, and W135 (9) (7) (14). Key tests for identification If N. meningitidis is suspected, blood will be drawn, and a lumbar puncture will be performed to grow cultures, perform serum tests, and test the cerebral spinal fluid for presence of the
2 pathogen (3)(5) (11) (19). It is also possible that a nasopharyngeal swab will be performed to look for the presence of the bacterium in the mucous membrane (7). Cultures may be successfully grown on blood or chocolate agar plates (10). A sample may be used to perform a Gram stain to look for the presence of Gram-negative diplococci characteristic of N. meningitidis (10). After culturing, the Kovac s oxidase test may be performed; if positive, then carbohydrate utilization tests will be completed in cystine trypticase agar (7) (10) (15). N. meningitidis will oxidize maltose and glucose, but not lactose or sucrose (7) (10) (15). Once completed, further testing for specific antigens/serogroups is done with slide agglutination tests. Depending on the facility, rapid diagnostic test strips coated in monoclonal antibodies might be available (10) (14). Additionally, polymerase chain reaction, PCR, may be used to identify the presence of N. meningitidis (14) (15) (16). Signs and symptoms of disease Major signs and symptoms are flu-like including fever, headache, vomiting, and stiff neck; confusion or altered mental status, photophobia, and rash are also likely. Signs and symptoms are somewhat different in infants and children including vomiting, irritability or distress, stiffness, lethargy, and decreased appetite (5) (7) (11) (12) (13). The onset of signs and symptoms may be rapid, and may not include all signs and symptoms depending on the location of the infection (blood and/or meninges) (5) (7) (11) (12). The incubation period of the disease is anywhere from 2 to 14 days, but the average is less than a week (9). Historical information The first likely case of meningococcal disease was documented during the 16 th Century, and in 1805 the first outbreak was noted in Switzerland; however, it was almost 100 years later when N. meningitidis was discovered in cerebral spinal fluid of infected patients (15) (16). Upon discovery of the etiologic agent, it was almost another 100 years before a vaccine was established and licensed for a single serogroup in the United States (16). Now there are several vaccines covering serogroups A, B, C, W, and Y in the United States (16) (17). Virulence Factors An important factor that increases N. meningitidis pathogenicity, or virulence, is the presence of a polysaccharide capsule which prevents engulfment by phagocytes (7). The bacterium is also able to produce IgA protease which is an enzyme that breaks down IgA antibodies produced by the body s immune system. The purpose of these antibodies is to prevent the attachment of infecting microorganisms to mucosal surfaces (18). Furthermore, since N. meningitidis is a Gramnegative bacterium, it produces endotoxins which cause many of the symptoms associated with the disease (18). With the ability to avoid phagocytes, destroy specific antibodies, and produce endotoxins, the bacterium has a greater chance of causing disease in the body. Control and Treatment
3 Since N. meningitidis is a bacterium, the best form of treatment is the use of antibiotics. A broad spectrum antibiotic may be used prior to confirmation of the presence of N. meningitidis; however, once verified, the use of penicillin is recommended (7) (14) (15) (16) (19). If allergies to penicillin are present, chloramphenicol or a third-generation cephalosporin may be substituted (7) (9). There are some strands with antibiotic resistance, but the occurrence of resistant strands is low in the United States (16). It is possible to use steroids for treatment as well to reduce the swelling caused by disease; however, this method of treatment is not used frequently (5). Furthermore, antibiotics may be given prophylactically in situations where an individual was in close contact with a person known to have the disease (3) (9) (11) (15). Prevention and Vaccine information The best form of prevention is vaccination; however, handwashing and avoiding those known to be ill are good preventative measures as well (3) (11) (13). Also, as previously described, antibiotics may be given prophylactically to prevent a secondary infection. Currently, there are three types of vaccines available in the US: a polysaccharide vaccine for A, C, W, and Y serogroups, several conjugate vaccines, and a recombinant vaccine for serogroup B (20). The polysaccharide vaccine, MPSV4, covers A, C, W, and Y serogroups, and contains purified bacterial capsular polysaccharides (16). One of the conjugate vaccines, MenACWY-D, contains polysaccharides of serotypes A, C, W, and Y conjugated with a diphtheria toxoid protein carrier (16). MenACWY-CRM is another conjugated vaccine that contains capsular polysaccharides of serogroups A, C, W, and Y as well, but in various amounts and in conjugation with CRM197 (16). The most recent conjugate vaccine is Hib-MenCY-TT. This vaccine contains capsular polysaccharides of serogroups C and Y of N. meningitidis, and serogroup B of Haemophilus influenzae conjugated to tetanus-toxoid (16). The recombinant vaccines of serogroup B contain recombinant surface proteins of N. meningitidis produced in Escherichia coli (21) (22). Another vaccine specifically for serogroup A has been available in Africa since 2005, and has greatly reduced the incidence rate of the disease in the region (30). Different vaccines are recommended in different situations depending on age, location, and risk of being infected. Students living in dorms, those traveling to locations with high rates of occurrence, those without a functioning spleen, and those serving in the military (3) (5) (6) (13). New Trials As the vaccine Trumenba was recently approved in 2014 by the USFDA, there is a current clinical trial in Oakland evaluating the immunogenicity of the vaccine for N. meningitidis serogroup B (23). The trial is currently in phase 4 so its purpose is to ensure there are no adverse side-effects or additional information not noted during phases 1 through 3 (24). There is also another trial in the US evaluating children who received the MenACWY-CRM vaccine between the ages of 2 months and 23 months (25). Another trial that is currently taking place in India is comparing the efficacy of ampicillin to ceftriaxone as a prophylaxis in traumatic brain injury patients involving air in the cranium (26).
4 Local cases or outbreaks According to the CDC in 2013, rates of meningococcal meningitis continued to be at historic lows (0.18 per 100, 000 population) with serogroup B primarily causing disease in infants and serogroups C, Y, or W causing 73% of disease in people older than 11 years of age (27). This incidence rate is down from 0.61 in 2003; the number of deaths is also down from 123 in 2005 to 26 in 2011 (27). There were two outbreaks involving serogroup B at campuses in New Jersey and California resulting in 13 cases and 1 death (27). There were a reported 556 cases in the US in 2013 including all serogroups with the highest number of cases in February and lowest in September; 30 of those cases reported for the year were in Texas (27). The lowest rates were seen in the year-old age range, and the highest in those younger than 1 year (27). Global cases or outbreaks (with incidence figures) The region known as the Meningitis Belt ranging from Gambia in Western Africa to Ethiopia in Eastern Africa is a hyper-endemic region for meningococcal meningitis with frequent epidemics (28). The majority of the cases were caused by serogroup A until formation of the vaccine MenAfriVac, and the rates of disease in this region are the highest in the world reaching up to 1,000 cases per 100, 000 (compared to the cases per 100,000 in the US, Australia, Europe, and South America) (14) (28). Nearly all countries in Africa were considered to have high endemic rates reaching up to almost 300 per 100, 000; while the US ranked amongst the lowest (post-vaccination) in 2009 with a rate at 0.3 per 100, 000 (31). Most recently there was an outbreak in Ghana beginning in late 2015 that has since spread to Togo (29). Since early 2016, 548 cases with 93 deaths have been reported in Ghana and over 800 cases with 70 deaths in Togo (29). Works Cited (1) Centers for Disease Control and Prevention. Meningococcal Disease. 4 Mar. Centers for Disease Control and Prevention May (2) Centers for Disease Control and Prevention. Causes and Transmission. 11 June Centers for Disease Control and Prevention: About the Disease May (3) Arnaud, S., Boisson, C., Martin, C., & Vialet, R. Severe community-acquired meningitis. National Center for Biotechnology Information: PMC. Crit care May (4) Bourdoulous, S., Coureuil, M., Join-Lambert, O., Lécuyer, H., Marullo, S., & Nassif, X. Mechanism of meningeal invasion by Neisseria meningitidis. National Center for Biotechnology Information. Virulence. 1 Mar May
5 (5) Johns Hopkins Medicine. Meningitis. Johns Hopkins Medicine: Health Library. ningitis_85,p00789/. 10 May (6) Centers for Disease Control and Prevention. Clinical Information. Centers for Disease Control and Prevention: Meningococcal Disease May (7) Morse, S. Chapter 14 Neisseria, Moraxella, Kingella, and Eikenella. Medical Microbiology. 4 th Edition. Ed. Baron, S. Galveston: University of Texas Medical Branch at Galveston, National Center for Biotechnology Information May (8) Edwards, A., Fahnert, B., Pryor, G., Strelkauskas, A., & Strelkauskas, J. Microbiology: A Clinical Approach. 2 nd Edition. Garland Science, May (9) Public Health Agency of Canada. Neisseria meningitidis. Public Health Agency of Canada: Pathogen Safety Data Sheet-Infectious Substances. 8 Sept May (10) Centers for Disease Control and Prevention. Chapter 7: Identification and Characterization of Neisseria meningitidis. Center for Disease Control and Prevention: Laboratory Methods for the Diagnosis of Meningitis. 15 Mar May (11) Vyas, J. M., Zieve, D., Ogilvie, I., & the A. D. A. M. Editorial team. Meningitis. US National Library of Medicine: Medline Plus. 7 Dec May (12) Centers for Disease Control and Prevention. Signs and Symptoms. Center for Disease Control and Prevention: Meningococcal Disease. 1 Apr May (13) Ben-Joseph, E. P. Infections: Meningitis. Kids Health from Nemours. The Nemours Foundation. Apr May (14) World Health Organization. Meningococcal Meningitis. World Health Organization: Fact Sheets. Nov May (15) Bhalla, P., Gupta, S., & Manchada, V. Meningococcal Disease: History, Epidemiology, Pathogenesis, Clinical Manifestations, Diagnosis, Antimicrobial Susceptibility, and
6 Prevention. Indian Journal of Medical Microbiology. Vol. 24. No. 1. Indian Journal of Medical Microbiology May (16) Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine- Preventable Diseases. Centers for Disease Control and Prevention: The Pink Book. 24 July May (17) Centers for Disease Control and Prevention. Serogroup B Meningococcal Vaccine. Texas Department of State Health Services: Vaccine Information Statements. 14 Aug May (18) Case, C., Funke, B., & Tortora, G. Microbiology: An Introduction. 12 th Edition. Pearson, , (19) Centers for Disease Control and Prevention. Diagnosis and Treatment. Centers for Disease Control and Prevention: Meningococcal Disease. 11 June May (20) National Center for Immunization and Respiratory Diseases. Meningococcal Vaccination. Centers for Disease Control and Prevention: Vaccines and Preventable Diseases. 22 Oct May (21) U.S. Food and Drug Administration. Package Insert-TRUMENBA. U.S. Food and Drug Administration. M pdf. 10 May (22) U.S. Food and Drug Administration. Package Insert-Bexsero. U.S. Food and Drug Administration. 23 Feb M pdf. 10 May (23) International Clinical Trials Registry Platform. Investigating the Immunogenicity of a U.S.- Licensed Meningococcal Serogroup B Vaccine (Trumenba). World Health Organization: International Clinical Trials Registry Platform May (24) Meningitis Vaccine Project. Clinical Trials. Meningitis Vaccine Project May (25) International Clinical Trials Registry Platform. Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study. World Health Organization: International Clinical Trials Registry Platform May 2016
7 (26) International Clinical Trials Registry Platform. Which antibiotic is better to prevent meningitis after head injury: Ampicillin or Ceftriaxone? World Health Organization: International Clinical Trials Registry Platform. 25 Apr May (27) Adams, D., Fullerton, K., Jajosky, R., Sharp, P., Onweh, D., Schley, A., the Nationally Notifiable Infectious Conditions Group. Summary of Notifiable Infectious Diseases and Conditions- United States Centers for Disease Control and Prevention: Morbidity and Mortality Weekly Report. 23 Oct May (28) Centers for Disease Control and Prevention. Chapter 3: Infectious Diseases Related to Travel. Centers for Disease Control and Prevention: Travelers Health. 10 July May (29) InterHealth Worldwide. Meningitis Outbreak In Ghana and Togo. InterHealth Worldwide. 10 Mar May (30) World Health Organization & PATH. Meningitis A nearly eliminated in Africa through vaccination, reaching more than 235 million people. African Health Observatory. 22 Feb May (31) Jafri, R., Ali, A., Messonnier, N., Tevi-Benissan, C., Durrheim, D., Eskola, J.,... Abramson, J. Global epidemiology of invasive meningococcal disease. National Center for Biotechnology Information. Population Health Metrics. Sept May
Meningococcal meningitis
Etiological Agent: Neisseria meningitis (1) Meningococcal meningitis By Tho Dao Transmission The transmission of Neisseria meningitis is through direct contact from person to person via droplets or throat
More informationMeningococcal Meningitis
Meningococcal Meningitis By Audrey Oh Etiologic Agent Neisseria meningitidis Transmission Neisseria meningitis is a bacterium that is often found in healthy, asymptomatic individuals [3]. Transmission
More informationMeningococcal meningitis
Meningococcal meningitis By Hollie Morales Disease: Meningococcal meningitis, also known as meningococcal disease, is a potentially fatal infection of the protective membranes which cover the brain and
More informationPneumococcal Meningitis Meningitis is an inflammation of the lining around the brain and spinal cord. Most severe cases
Pneumococcal Meningitis Meningitis is an inflammation of the lining around the brain and spinal cord. Most severe cases are caused by bacteria. Pneumococcal bacteria (Streptococcus pneumoniae) are the
More informationHaemophilus influenzae
Haemophilus influenzae type b Severe bacterial infection, particularly among infants During late 19th century believed to cause influenza Immunology and microbiology clarified in 1930s Haemophilus influenzae
More informationPre-Lec. + Questions
Sheet 14 (part 2) made by : Majd abu-fares corrected by: Shatha khtoum date:8/11/2016 Pre-Lec. + Questions *Pus: secretion of {WBCs + product of WBCs + product of M.O} *WBCs can produce enzymes cytokines
More information9/12/2018. Meningococcal Disease and Meningococcal Vaccine. Neisseria meningitidis. Meningococcal Disease Pathogenesis. Aerobic gram-negative bacteria
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Meningococcal Disease and Meningococcal Vaccine Adult Track Chapter 14 Photographs and images included
More informationThis genus includes two species pathogenic for humans:
THE GENUS NEISSERIA Neisseriae are gramnegative cocci arranged in pairs, so they are diplococci. This genus includes two species pathogenic for humans: N. gonorrhoeae (s.c. gonococci) N. meningitidis (s.c.
More informationStreptococcus Pneumoniae
Streptococcus Pneumoniae (Invasive Pneumococcal Disease) DISEASE REPORTABLE WITHIN 24 HOURS OF DIAGNOSIS Per N.J.A.C. 8:57, healthcare providers and administrators shall report by mail or by electronic
More informationGram-Negative Cocci :Neisseria & Vibrio
Sulaimani University College of Pharmacy Microbiology Lec. 7 Gram-Negative Cocci :Neisseria & Vibrio Dr. Abdullah Ahmed Hama PhD. Microbiology/Molecular Parasitology abdullah.hama@spu.edu.iq 1 Neisseria
More informationHaemophilus influenzae type B and Hib Vaccine Chapter 9
Haemophilus influenzae type B and Hib Vaccine Chapter 9 Haemophilus influenzae Aerobic gram-negative bacteria Polysaccharide capsule Six different serotypes (a-f) of polysaccharide capsule 95% of invasive
More informationNational Institute for Communicable Diseases -- Weekly Surveillance Report --
Weekly Surveillance Report Week 43, 216 National Institute for Communicable Diseases -- Weekly Surveillance Report -- Page 2 Laboratory-Based Respiratory & Meningeal Disease Surveillance 3 Neisseria meningitidis
More informationMENINGOCOCCAL MENINGITIS 101. An Overview for Parents, Teachers, Students and Communities
MENINGOCOCCAL MENINGITIS 101 An Overview for Parents, Teachers, Students and Communities 2013 Meningococcal Disease Fast Facts Meningococcal disease is the result of a rare, but serious bacterial infection
More informationMeningococcal Disease and College Students
MASSACHUSETTS PUBLIC HEALTH FACT SHEET Meningococcal Disease and College Students May 2018 Page 1 of 4 What is meningococcal disease? Meningococcal disease is caused by infection with bacteria called Neisseria
More informationSHOTS! THE GET. Facts About HPV and Meningitis
GET THE SHOTS! Facts About HPV and Meningitis HUMAN PAPILLOMAVIRUS What is HPV? You may have heard a lot of talk recently about HPV. But what is it, exactly? HPV, or the human papillomavirus, is the most
More informationREQUIRED IMMUNIZATIONS
REQUIRED IMMUNIZATIONS Pre-Kindergarten 4 DTP/DTaP/TD, 3 OPV (Polio), 1 MMR, 3 HEP B, 2 HEP A, 1 VARICELLA Kindergarten-6 th Grade 5 DTP/DTaP/TD, 4 OPV (Polio), 2 MMR, 3 HEP B, 2 HEP A, 1 VARICELLA All
More informationGlobal Burden of Meningococcal Disease. Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci. Centre for Global Health Security, Chatham House, London.
Global Burden of Meningococcal Disease Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci. Centre for Global Health Security, Chatham House, London. Neisseria meningitidis Gram negative diplococci. Ten
More informationHaemophilus influenzae, Invasive Disease rev Jan 2018
Haemophilus influenzae, Invasive Disease rev Jan 2018 BASIC EPIDEMIOLOGY Infectious Agent Haemophilus influenzae (H. influenzae) is a small, Gram-negative bacillus, a bacterium capable of causing a range
More informationBacterial Meningitis Concerns in Collegiate Athletics.5 hr. CEU
Bacterial Meningitis Concerns in Collegiate Athletics.5 hr. CEU This unit is designed to increase your understanding of a highly dangerous infection, and help you protect your student athletes from its
More informationMeningococcal Invasive Disease
Meningococcal Invasive Disease Communicable Disease Control Unit NOTE: The main difference between this and previous protocols is reporting and management of meningococcal conjunctivitis. Criteria for
More informationMeningococcal Disease in Travellers
Meningococcal Disease in Travellers Please find product Prescribing Information at the end of this presentation Meningococcal disease A rare but potentially serious illness in travellers1 Caused by the
More informationAppendix A: Disease-Specific Chapters
Ministry of Health and Long-Term Care Infectious Diseases Protocol Appendix A: Disease-Specific Chapters Chapter: Haemophilus influenzae disease, all types, invasive Effective: May 2018 Haemophilus influenzae,
More informationVACCINATION CONVERSATION GUIDE
VACCINATION CONVERSATION GUIDE A helpful tool for discussing vaccines with your patients 2017 GSK group of companies. All rights reserved. Produced in USA. 817419R0 February 2017 How this guide works:
More informationMicrobiology With Diseases by Taxonomy
Microbiology With Diseases by Taxonomy Second Edition PowerPoint Lecture Slides 14 Infection, Infectious Diseases, and Epidemiology SARS: Severe Acute Respiratory Syndrome 2003 Chapter opener 14 Chapter
More informationInvestigation of a Neisseria meningitidis Serogroup A Case in the Meningitis Belt. January 2017
January 2017 Investigation of a Neisseria meningitidis Serogroup A Case in the Meningitis Belt Introduction Since the progressive introduction of meningococcal serogroup A conjugate vaccine (MACV) in the
More informationCentral Nervous System Infection
Central Nervous System Infection Lingyun Shao Department of Infectious Diseases Huashan Hospital, Fudan University Definition Meningitis: an inflammation of the arachnoid membrane, the pia mater, and the
More informationFoundations in Microbiology
Foundations in Microbiology Fifth Edition Talaro Chapter 13 Microbe Human Interactions: Infection and Disease Chapter 13 2 3 Infection a condition in which pathogenic microbes penetrate host defenses,
More informationCAMP GUGGENHEIM. Update March 2018
CAMP GUGGENHEIM PO BOX 369 100 ELIZABETH STREET OGDENSBURG, NEW YORK 13669 TELEPHONE: 315.393.2920 ext. 1401 FAX: 866.314.7296 http://www.rcdony.org/youth.html Update March 2018 Dear Parent or Guardian:
More informationThe Florida Bureau of Immunization Wants to See CALL THE PSA TOOLKIT. Need Additional Info?
YOUSHOTS! CALL THE The Florida Bureau of Immunization Wants to See PSA TOOLKIT Need Additional Info? Email ShotsPSAContest@brunetgarcia.com The Bureau of Immunization Wants to See You Call the Shots The
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Management of meningitis and meningococcal disease in children and young people in primary and secondary care. 1.1 Short title
More informationShelter-based Meningococcal Disease Outbreak: Working together to treat and vaccinate
Shelter-based Meningococcal Disease Outbreak: Working together to treat and vaccinate Barbara Giles, MSN, RN April Donahue, BSN, RN Denise De Las Nueces, MD, MPH Boston Health Care for the Homeless Program
More information5/14/2015. Meagan Burns, MPH Massachusetts Adult Immunization Conference April relevant conflict. Grant Research/Support
Meagan Burns, MPH Massachusetts Adult Immunization Conference April 2015 Consultant Grant Research/Support Speaker s Bureau Major Stockholder Other Financial or Material Interest Off Label Use of Vaccines
More informationWelcome to Pathogen Group 4
Welcome to Pathogen Group 4 Chlamydia trachomatis Trachoma Genital chlamydia Chlamydophila (Chlamydia) psittaci Bacillus anthracis Neisseria meningitidis Haemophilus influenzae, type B Helicobacter pylori
More informationMedical Bacteriology- Lecture 13 Gram Negative Coccobacilli Haemophilus Bordetella
Medical Bacteriology- Lecture 13 Gram Negative Coccobacilli Haemophilus Bordetella 1 Haemophilus "loves heme" Small gram-negative coccobacilli Non-spore forming Non-motile Growth is enhanced in CO2 Present
More informationGUIDELINE FOR THE MANAGEMENT OF MENINGITIS. All children with suspected or confirmed meningitis
GUIDELINE FOR THE MANAGEMENT OF MENINGITIS Reference: Mennigitis Version No: 1 Applicable to All children with suspected or confirmed meningitis Classification of document: Area for Circulation: Author:
More informationCNS Infections. GBS Streptococcus agalactiae. Meningitis - Neonate
CNS Infections GBS Streptococcus agalactiae Bacterial meningitis - Pathophysiology - general Specific organisms - Age Hosts Treatment/Prevention Distinguish from viral disease Common commensal flora childbearing
More informationS404- Meningococcal Vaccines: Updated Policy Statement 2014
S404- Meningococcal Vaccines: Updated Policy Statement 2014 Michael T. Brady, MD Associate Medical Director Nationwide Children s Hospital Columbus, Ohio Disclosure of Relevant Relationship Dr. Brady (or
More informationAlberta Health and Wellness Public Health Notifiable Disease Management Guidelines August Pneumococcal Disease, Invasive (IPD)
August 2011 Pneumococcal Disease, Invasive (IPD) Revision Dates Case Definition Reporting Requirements Remainder of the Guideline (i.e., Etiology to References sections inclusive) Case Definition August
More informationMedical Bacteriology Lecture 15
Medical Bacteriology Lecture 15 Gram Negative Coccobacilli Haemophilus Bordetella pertussis Haemophilus "loves heme" small gram-negative coccobacilli, non-spore forming, non-motile, require enriched media
More informationVaccination Policy. Background: Meningococcal Disease on Campus
Vaccination Policy EDMC institutions shall recognize all state and federal vaccination and immunization requirements. Institutions, with the support of EDMC regulatory affairs and compliance and legal
More information2/16/2015 IMMUNIZATION UPDATE Kelly Ridgway, RPh February 21, Today s Overview NEW RECOMMENDATIONS
IMMUNIZATION UPDATE 2015 Kelly Ridgway, RPh February 21, 2015 Today s Overview 1 2 3 4 5 6 Pneumococcal Vaccine Recommendations Meningococcal Vaccine Recommendations HPV Vaccine Recommendations Patient
More informationBacteriology cont d. Dr. Hamed Al-Zoubi
Bacteriology cont d Dr. Hamed Al-Zoubi Listeria g+ve rods Neisseria -ve Haemophilus influenzae -ve Bordetella -ve Listeria monocytogenes: Differential characteristics: Gram positive, non-spore forming,
More informationBacteriology cont d. Dr. Hamed Al-Zoubi. Listeria g+ve rods Neisseria -ve Haemophilus influenzae -ve Bordetella -ve
Bacteriology cont d Dr. Hamed Al-Zoubi Listeria g+ve rods Neisseria -ve Haemophilus influenzae -ve Bordetella -ve Listeria monocytogenes: Differential characteristics: Gram positive, non-spore forming,
More informationLecture 4. Gonococci : 1) do not have capsules 2) They have plasmids 3) They cause genital infection 4) Ferment glucose only
Lecture 4 Genus Neisseriae The Neisseria species are gram negative cocci that usually occur in pairs, Neisseria gonorrhea gonococci and Neisseria meningitidis meningococci are pathogenic for human and
More informationB 型嗜血感冒桿菌感染及 其疫苗 衛生署疾病管制局 中區傳染病防治醫療網 王任賢指揮官
B 型嗜血感冒桿菌感染及 其疫苗 衛生署疾病管制局 中區傳染病防治醫療網 王任賢指揮官 Haemophilus influenzae type b Severe bacterial infection, particularly among infants During late 19th century believed to cause influenza Immunology and microbiology
More informationYersinia pestis. Yersinia and plague. Dr. Hala Al Daghistani
Yersinia pestis Dr. Hala Al Daghistani Yersinia species Short, pleomorphic gram-negative rods that can exhibit bipolar staining. Catalase positive, and microaerophilic or facultatively anaerobic. Animals
More informationBacterial diseases caused by Streptoccus pneumoniae in children
Bacterial diseases caused by Streptoccus pneumoniae in children Bactermia 85% Bacterial pneumonia 66% Bacterial meningitis 50% Otitis media 40% Paranasal sinusitis 40% 0% 10% 20% 30% 40% 50% 60% 70% 80%
More informationMeningococcal Disease Information and Investigation Guidelines
Meningococcal Disease Information and Investigation Guidelines Table of Contents: 1) Disease Description... 2 2) Infectious Agent... 2 3) Symptoms... 2 4) Incubation Period... 2 5) Incidence... 3 6) Transmission...
More informationPATHOGENICITY OF MICROORGANISMS
PATHOGENICITY OF MICROORGANISMS Some microorganisms are : 1- Harmless microorganism, as normal flora 2- Harmfull microorganism, as pathogenic. A pathogenic microorganism is defined as one that causes or
More informationDevelopment of a Group A meningococcal conjugate vaccine for sub-saharan Africa: clinical trial results
Development of a Group A meningococcal conjugate vaccine for sub-saharan Africa: clinical trial results Global Immunization Meeting 2009, United Nations HQ New York City, February 2009 MenA conjugate vaccine
More informationHow It Spreads Symptoms Can Include Complications
OUR BEST SHOT: The Importance of Vaccines for Older Adults VACCINES QUICK GUIDE TO VACCINATION FOR ADULTS AGES 60+ Vaccines are an important step in protecting your health and the health of your family.
More informationEmerging Infectious Disease (5): Meningococcal Disease
S73 Meningococcal Disease Emerging Infectious Disease (5): Meningococcal Disease Chuan-Ting Yeh, MD; Chu-Mei Lin, MD; Tzong-Luen Wang, MD, PhD Abstract Meningococcal disease is a serious, potentially life-threatening
More informationManaging meningitis epidemics in Africa. A quick reference guide for health authorities and health-care workers
Managing meningitis epidemics in Africa A quick reference guide for health authorities and health-care workers WHO/HSE/GAR/ERI/2010.4 Managing meningitis epidemics in Africa A quick reference guide for
More informationWHAT S NEW WITH VACCINATIONS IN 2016?
WHAT S NEW WITH VACCINATIONS IN 2016? MenB and a Few Other Changes Lynn Bahta, RN, PHN Immunization Clinical Consultant Minnesota Department of Health May 2016 Disclosure No conflict of interest Will discuss
More informationInfluenza. By Allison Canestaro-Garcia. Disease Etiology:
Influenza By Allison Canestaro-Garcia Disease Etiology: The flu is an infectious disease caused by a subset of viruses of the family Orthomyxoviridae. There are 7 different viruses in this family, four
More informationLocal Public Health Department. Communicable diseases Environmental health Chronic diseases Emergency preparedness Special programs
Susan I. Gerber, MD Local Public Health Department Communicable diseases Environmental health Chronic diseases Emergency preparedness Special programs Public Health Reporting Ground Zero Local government
More informationVaccines. Robert Read University of Southampton University Hospital Southampton
Vaccines Robert Read University of Southampton University Hospital Southampton Disclosures Non personal, non specific; Novartis-GSK Member, JCVI Editor in Chief, Journal of Infection, and Current Opinion
More informationReading: Chapter 13 (Epidemiology and Disease) in Microbiology Demystified
Biology 100 Winter 2013 Reading Guide 02 Reading: Chapter 13 (Epidemiology and Disease) in Microbiology Demystified Directions: Fill out the reading guide as you read. Again, the reading guide is designed
More informationAurora Health Care South Region EMS st Quarter CE Packet
Name: Dept: Date: Aurora Health Care South Region EMS 2010 1 st Quarter CE Packet Meningitis Meningitis is an inflammatory disease of the leptomeninges. Leptomeninges refer to the pia matter and the arachnoid
More informationDEMOGRAPHIC INFORMATION
135 Forsyth Building Northeastern University 360 Huntington Avenue Boston, MA 02115 617.373.2772 (voice) 617.373.2601 (fax) 617.373.5973 (TTY) uhcs@northeastern.edu Health Report Massachusetts law requires
More informationUnion Theological Seminary Measles, Mumps & Rubella Form
Union Theological Seminary Measles, Mumps & Rubella Form Please return this form by fax: (212) 202-4667) or by mail/in person: Office of Student Affairs, Union Theological Seminary, 3041 Broadway, New
More informationBCHOOSE TO VACCINATED. Ask your doctor about the MenB * vaccine.
BCHOOSE TO VACCINATED Vaccinate against meningococcal disease caused by Neisseria meningitidis group B strains (MenB) with BEXSERO BEXSERO multicomponent meningococcal B vaccine (recombinant, adsorbed)
More informationPneumococcal Disease and Pneumococcal Vaccines
Pneumococcal Disease and Epidemiology and Prevention of - Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at
More informationBurton's Microbiology for the Health Sciences
Burton's Microbiology for the Health Sciences Chapter 11. Epidemiology and Public Health Chapter 11 Outline Epidemiology Interactions Among Pathogens, Hosts and the Environment Chain of Infection Reservoirs
More informationBiology of Neisseria meningitidis: implications for vaccine development Richard Moxon: University of Oxford
Biology of Neisseria meningitidis: implications for vaccine development Richard Moxon: University of Oxford Biology of N.meningitidis infection Within hours, the disease may progress to shock with multi-organ
More informationRabies. By Rosa Reynoso. Rabies; Etiological Agent: Rhabdoviridae family Lyssavirus genus type (4)
Rabies By Rosa Reynoso Rabies; Etiological Agent: Rhabdoviridae family Lyssavirus genus type (4) Transmision: It is a zoonotic disease transmitted from infected animals to humans (4). Infected animals
More informationSplenectomy Vaccine Protocol PIDPIC
Splenectomy Vaccine Protocol PIDPIC 6.24.14 Rationale Spleen clears encapsulated bacteria and infected erythrocytes Serves as one of the largest lymphoid tissues where B cells are educated against encapsulated
More informationMeningococcal Disease a resurgence of an old foe?
Meningococcal Disease a resurgence of an old foe? To talk about NZ rates of meningococcal disease Changing serotypes Clinical presentations Meningococcal vaccines What is meningococcal disease? Important
More informationPertussis: An Emerging Infection. Holly K. Ehrke. Ferris State University
Running head: PERTUSSIS AN EMERGING INFECTION 1 Pertussis: An Emerging Infection Holly K. Ehrke Ferris State University PERTUSSIS AN EMERGING INFECTION 2 Abstract Pertussis is a highly contagious disease
More informationPediatric and Adolescent Vaccines
Pediatric and Adolescent Vaccines Andrea A. Berry, M.D. Division of Infectious Diseases and Tropical Pediatrics Center for Vaccine Development & Division of Malaria Research Overview Pediatric vaccine
More informationIntroduction of a meningococcal ACWY immunisation programme for adolescents
Introduction of a meningococcal ACWY immunisation programme for adolescents Information for registered healthcare practitioners Acknowledgement: This resource has been adapted with the permission of Public
More informationMedicine - Dr. Hawar - Lecture 5 - CNS Infections I
Medicine - Dr. Hawar - Lecture 5 - CNS Infections I Infections of the nervous system can be caused by viruses, bacteria, fungi or protozoa. They may affect the lining of the brain, CSF, brain parenchyma,
More informationCSLO8. Explain transmission and virulence mechanisms of cellular and acellular infectious agents.
PowerPoint Lecture Presentations prepared by Mindy Miller-Kittrell, North Carolina State University CSLO8. Explain transmission and virulence mechanisms of cellular and acellular infectious agents. C H
More informationRequired Health Form
Health Services Wellness Center Phone: (845) 569-3152 Fax: (845) 569-3514 Required Health Form Part-Time Undergraduates and All Graduate Students New York State Public Health Law requires that all students
More informationCholera. By Cate Turner. Name Common Name: Cholera Etiologic agent: V ibrio cholerae (1)
Cholera By Cate Turner Name Common Name: Cholera Etiologic agent: V ibrio cholerae (1) Transmission Vibrio cholerae i s transmitted by the fecal-oral route by infection of epithelial cells in the small
More informationBelow you will find information about diseases, the risk of contagion, and preventive vaccinations.
Vaccinations Below you will find information about diseases, the risk of contagion, and preventive vaccinations. DTP - Diphtheria Tetanus Polio Yellow fever Hepatitis A Typhoid fever Cerebrospinal meningitis
More informationNSW Annual Vaccine-Preventable Disease Report, 2009
NSW Annual Vaccine-Preventable Disease Report, 29 Paula J. Spokes A,B and Robin E. Gilmour A A Communicable Diseases Branch, NSW Department of Health B Corresponding author. Email: pspok@doh.health.nsw.gov.au
More informationPediatric and Adolescent Infectious Disease Concerns
Pediatric and Adolescent Infectious Disease Concerns Sean P. Elliott, MD Professor of Pediatrics Associate Chair of Education, Department of Pediatrics University of Arizona College of Medicine Tucson,
More informationUpper Respiratory Infections. Mehreen Arshad, MD Assistant Professor Pediatric Infectious Diseases Duke University
Upper Respiratory Infections Mehreen Arshad, MD Assistant Professor Pediatric Infectious Diseases Duke University Disclosures None Objectives Know the common age- and season-specific causes of pharyngitis
More informationImmunization Update: New CDC Recommendations. Blaise L. Congeni M.D. 2012
Immunization Update: New CDC Recommendations Blaise L. Congeni M.D. 2012 Polysaccharide Vaccines Vaccine Hib capsule polysaccharide PRP (polyribose ribitol phosphate) Not protective in infants
More informationMeningococcal Meningitis Vaccine (NmVac-2 A+ C ) Meningococcal Polysaccharide Vaccine Groups A+ C Combined
How is meningitis transmitted? Meningococcal Meningitis Vaccine (NmVac-2 A+ C ) Meningococcal Polysaccharide Vaccine Groups A+ C Combined Neisseria meningitidis causes meningitis disease in infants, children
More informationHealth care workers and infectious diseases
Introduction Health care workers and infectious diseases Objectives 1. What is an infectious disease?? 2. What is an infection and disease?? 3. Causes of re-emerging of the problem of the infectious diseases
More informationVaccine Preventable Diseases. Overview MEASLES 4/8/2015. Amy Schwartz, MPH Immunization Surveillance Coordinator North Dakota Department of Health
Vaccine Preventable Diseases Amy Schwartz, MPH Immunization Surveillance Coordinator North Dakota Department of Health Measles Mumps Pertussis Meningococcal Disease Polio Rubella Hepatitis A Overview MEASLES
More informationMeningococcal Meningitis is a rare bacterial infection.
Meningococcal Meningitis is a rare bacterial infection. Scanning Electron Microscope image of bacterial Meningitis Christine Cheng, University of Oklahoma Meningitis at 10x magnification MicroscopyU.com
More informationHemagglutinin Neuraminidase
Evolving Vaccine Guidance: Influenza, Meningococcal & HPV Vaccines H. Cody Meissner, M.D. Professor of Pediatrics Tufts University School of Medicine Maine Chapter AAP Bar Harbor, Maine October 16, 2016
More informationImmunity and how vaccines work
Immunity and how vaccines work Dr Mary O Meara National Immunisation Office Objectives of session An understanding of the following principles Overview of immunity Different types of vaccines and vaccine
More informationM I C R O B I O L O G Y WITH DISEASES BY TAXONOMY, THIRD EDITION
M I C R O B I O L O G Y WITH DISEASES BY TAXONOMY, THIRD EDITION Chapter 14 Infection, Infectious Diseases, and Epidemiology Lecture prepared by Mindy Miller-Kittrell, University of Tennessee, Knoxville
More informationHow to Detect and Confirm Epidemic Meningococcal Disease
How to Detect and Confirm Epidemic Meningococcal Disease Men/Detect & Confirm/1 Detection and Confirmation of Epidemic Meningococcal Disease 1. Maintain surveillance Health facilities report suspected
More informationFrom Sticky Mucus to Probing our Past: Aspects and problems of the Biotechnological use of Macromolecules
From Sticky Mucus to Probing our Past: Aspects and problems of the Biotechnological use of Macromolecules Carbohydrate Vaccines Macromolecules as Vaccines Steve Harding Vaccination Vaccine produces immunity
More informationDisclosure Statement. Encapsulated Bacteria. Functions of the Spleen 10/25/2017. Pharmacist Learning Objectives
Pharmacist Learning Objectives No Spleen? No Problem. A Review of Vaccinations Indicated for the Asplenic Patient SCSHP Fall Meeting October 26, 2017 Explain the rationale for vaccinations in Select the
More informationEnvironmental survival of Neisseria meningitidis
Environmental survival of Neisseria meningitidis Yih-Ling Tzeng, Emory University L.E. Martin, Emory University David Stephens, Emory University Journal Title: Epidemiology and Infection Volume: Volume
More informationDilemmas in the Management of Meningitis & Encephalitis HEADACHE AND FEVER. What is the best initial approach for fever, headache, meningisums?
Dilemmas in the Management of Meningitis & Encephalitis Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine HEADACHE AND FEVER What is the best initial approach for fever,
More informationBacterial infections of central nervous system Microbiology lec. #4 (bacteriology 1) Dr. Asem Shehabi
Bacterial infections of central nervous system Microbiology lec. #4 (bacteriology 1) Dr. Asem Shehabi This sheet includes only extra information not mentioned in the slides So you should refer to the slides.
More informationInfluenza. Gwen Clutario, Terry Chhour, Karen Lee
Influenza Gwen Clutario, Terry Chhour, Karen Lee Overview Commonly referred to as the flu Defined as a highly contagious viral infection where it starts at the upper respiratory tract and attacks the nose,
More informationDiphtheria. Vaccine Preventable Childhood Diseases. General information
Diphtheria General information Caused by the bacterium Corynebacterium diphtheria. Transmission is most often person-to-person spread via respiratorydroplets. The word diphtheria comes from Greek and means
More informationBACTERIAL MENINGITIS: A FIVE YEAR ( ) RETROSPECTIVE STUDY AT UNIVERSITY MALAYA MEDICAL CENTer (UMMC), KUALA LUMPUR, MALAYSIA
BACTERIAL MENINGITIS: A FIVE YEAR (2001-2005) RETROSPECTIVE STUDY AT UNIVERSITY MALAYA MEDICAL CENTer (UMMC), KUALA LUMPUR, MALAYSIA H Erleena Nur, I Jamaiah, M Rohela and V Nissapatorn Department of Parasitology,
More information3/10/2017. Overview N.J.A.C. 8:57-6. Purpose of N.J.A.C. 8:57-6. New Jersey Higher Education Immunization Requirements
N.J.A.C. 8:57-6 New Jersey Higher Education Immunization Requirements Jenish Sudhakaran, MPH Population Assessment Coordinator Vaccine Preventable Disease Program New Jersey Department of Health NJCHA
More informationInfection, Infectious Diseases, and Epidemiology
PowerPoint Lecture Presentations prepared by Mindy Miller-Kittrell, North Carolina State University C H A P T E R 14 Infection, Infectious Diseases, and Epidemiology Symbiotic Relationships Between Microbes
More informationMeningitis January Dr Andrew Lee Consultant in Communicable Disease Control, PHE Information in this slide set was correct as of 21.1.
Meningitis January 2016 Dr Andrew Lee Consultant in Communicable Disease Control, PHE Information in this slide set was correct as of 21.1.16 Outline What is meningitis What causes it What are the signs
More information